Modern Therapy for Gout through the Prism of Efficacy and Safety

I.Yu. Golovach

Abstract


The modern data on the treatment of such common condition as gout were presented in this article. Gout management covers and unites two directions: firstly, adequate treatment of acute gout episodes and, secondly, a steady decline in serum urate level below 360 µmol/l (6 mg/dl) or lower in some cases to prevent recurrences and to promote resorption of tophi. The therapeutic possibilities in acute gout episode include nonsteroidal anti-inflammatory drugs, colchicine and glucocorticoids; in the treatment of chronic gout, allopurinol is widely used. The efficacy and safety of innovative drugs in the treatment of gout — febuxostat and interleukin-1 inhibitors were shown. It is underlined that the main problems of gout treatment are related to long-term safety and comorbidities.


Keywords


gout; hyperuricemia; antigout agents; drug interactions; allopurinol; febuxostat; pegloticase; safety; efficacy of treatment

References


Алекберова З.С., Барскова В.Г. Колхицин в ревматологии — вчера и сегодня. Будет ли завтра? // Совр. ревматология. — 2010. — № 2. — С. 25-29.

Барскова В.Г., Ильина А.Е. Рациональные подходы к диагностике и лечению подагры (по материалам рекомендаций Европейской антиревматической лиги) // Клиницист. — 2010. — № 1. — С. 78-82.

Барскова В.Г., Ильиных Е.В., Насонов Е.Л. Фебуксостат — новый препарат в терапии подагры // Научно-практ. ревматология. — 2011 — № 2. — С. 52-58.

Елисеев М.С., Барскова В.Г., Насонов Е.Л. Канакинумаб (ингибитор интерлейкина-1β) — прорыв в возможностях противовоспалительной терапии при подагре // Научно-практ. ревматология. — 2013. — № 4(51). — С. 428-431.

Мясоедова С.Е., Кожевникова Е.А. Новые возможности коррекции гиперурикемии при подагре // Совр. ревматология. — 2009. — № 4. — С. 37-39.

Becker M., Baraf H., Yood R. et al. Long-termsafety of pegloticase in chronic gout refractory to conventional treatment // Ann. Rheum. Dis. — 2013. — Vol. 72. — P. 1469-1474.

Becker M.A., Schumacher H.R., Wortmann R.L. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout // New Engl. J. ed. — 2005. — Vol. 8. — P. 2450-2461.

Ben-Chetrit E., Bergmann S., Sood R. Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis // Rheumatology. — 2006. — Vol. 45(3). — P. 274.

Chiu M., Hu M., Ng M. et al. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong // Br. J. Dermatol. — 2012. — Vol. 167. — P. 44-49.

Crittenden D.B., Lehmann R.A., Schneck L. et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout // J. Rheumatol. — 2012. — Vol. 39. — P. 1458-1464.

Edwards N.L. Febuxostat: a new treatment for hyperuricaemia in gout // Rheumatology. — 2009. — Vol. 48. — P. 15-19.

Hande K., Noone R., Stone W. Severe allopurinol toxi­city. Description and guidelines for prevention in patients with renal insufficiency // Am. J. Med. — 1984. — Vol. 76. — P. 47-56.

Hershfield M.S., Callaghan J.T., Tassaneeyakul W. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing // Clin. Pharmacol. Ther. — 2013. — Vol. 93. — P. 153-158.

Horikoshi R., Akimoto T., Inoue M. et al. Febuxostat for hyperuricaemia: experience with patients on chronic hemodialysis treatment // Clin. Exp. Nephrol. — 2013. — Vol. 17. — P. 149-150.

Khanna D., Khanna P., Fitzgerald J. et al. 2012 American College of Rheumatology Guidelines for the Management of Gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis // Arthritis Care Res. — 2012. — Vol. 4. — P. 1447-1461.

McLean L., Becker M.A. The pathogenesis of gout // Rheumatology Fourth Edition / Edited by M.C. Hochberg, A.J. Silman, J.S. Smolen et al. — Phyladelphia, 2008. — P. 1813-27.

Mitha E., Schumacher H., Fouche L. et al. Rilonacept for acute gout flare during initiation of uric acid lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial // Rheumatology. — 2013. — Vol. 52. — P. 1285-1292.

Nidorf S., Eikelboom J., Budgeon C. et al. Low-dose colchicine for secondary prevention of cardiovascular disease // J. Am. Coll. Cardiol. — 2013. — Vol. 61. — P. 404-410.

Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation // Curr. Rheumatology Rep. — 2008. — Vol. 10(3). — P. 218-227.

Perez-Ruiz F., Dalbeth N., Bardin T.A. Review of Uric Acid, Crystal Deposition Disease, and Gout // Adv. Ther. — 2015. — Vol. 32. — P. 31-41.

Pope R., Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy // Arthritis Rheum. — 2007. — Vol. 56. — P. 3183-3188.

Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) // Am. Heart J. — 2011. — Vol. 162. — P. 597-605.

Schlesinger N., Alten R., Bardin T. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double blind trials and their initial extensions // Ann. Rhem. Dis. — 2012. — Vol. 71. — P. 1839-1848.

Seth R., Kydd A.S., Buchbinder R. et al. Allopurinol for chronic gout // Cochrane Database Syst. Rev. — 2014. — Vol. 14. — 10 p.

Stamp L.K. Safety Profile of Anti-gout Agents: An Update // Curr. Opin. Rheumatol. — 2014. — Vol. 26(2). — P. 162-168.

Stamp L., Taylor W., Jones P. et al. Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol // Arthritis Rheum. — 2012. — Vol. 64. — P. 2529-2536.

Sundy J., Baraf H., Yood R. et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials // J. Am. Med. Assoc. — 2011. — Vol. 306. — P. 711-720.

Sunkureddi P., Bardin T., Alten R. et al. Efficacy and safety of canakinumab in gouty arthritis patients with chronic kidney disease stage ≥ 3 // Ann. Rheum. Dis. — 2012. — Vol. 71 (Suppl. 3). — P. 447.

Terkeltaub R., Furst D., Bennett K. et al. High versus low dosing of oral colchicine for early acute gout flare // Arthritis Rheum. — 2010. — Vol. 62. — P. 1060-1068.

White W.B., Chohan S., Dabholkar A. et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities // Am. Heart J. — 2012. — Vol. 164. — P. 14-20.




DOI: https://doi.org/10.22141/2224-1507.2.18.2015.79100

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 PAIN. JOINTS. SPINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru